<code id='CAA34731A6'></code><style id='CAA34731A6'></style>
    • <acronym id='CAA34731A6'></acronym>
      <center id='CAA34731A6'><center id='CAA34731A6'><tfoot id='CAA34731A6'></tfoot></center><abbr id='CAA34731A6'><dir id='CAA34731A6'><tfoot id='CAA34731A6'></tfoot><noframes id='CAA34731A6'>

    • <optgroup id='CAA34731A6'><strike id='CAA34731A6'><sup id='CAA34731A6'></sup></strike><code id='CAA34731A6'></code></optgroup>
        1. <b id='CAA34731A6'><label id='CAA34731A6'><select id='CAA34731A6'><dt id='CAA34731A6'><span id='CAA34731A6'></span></dt></select></label></b><u id='CAA34731A6'></u>
          <i id='CAA34731A6'><strike id='CAA34731A6'><tt id='CAA34731A6'><pre id='CAA34731A6'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:68963
          Portrait of R. Shawn Martin -- health coverage from STAT
          R. Shawn Martin, the CEO of the American Academy of Family Physicians Courtesy American Academy of Family Physicians

          In ten years, the United States could be short as many as 48,000 primary care doctors. The specialty is underpaid, to a point that doctors are lobbying Medicare to pay it extra. Even medical residents who chose the specialty are leaving primary care; some 45% of residents who planned to be generalists changed their mind during their residencies.

          But R. Shawn Martin, the CEO of the American Academy of Family Physicians, the specialty trade group, isn’t worried.

          advertisement

          “I’ve been around this and at this a long time and family medicine and primary care’s obituary has been written many times in my 25-plus years of doing this work,” he said with a laugh. “This isn’t the first time that primary care has been dying or fading away.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Diverse clinical trials: Why aren’t we there yet?
          Diverse clinical trials: Why aren’t we there yet?

          KeishaOkaforforSTATClinicaltrialsarecriticaltoadvancinglifesavingmedicationsandtreatments.ButtheU.S.

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Will the IRA bring competition to the biologics market?

          AdobeOnAug.29,Medicarereleaseditshighlyanticipatedlistof10therapiesforwhichitplanstoestablishapriceb